Application of immunotherapy in malignant pleural mesothelioma_Chinese Journal of Clinical Thoracic and Cardiovascular Surgery

Authors：

CHEN Xiang , ZHANG Yajie ,  LI Hecheng

Department of Thoracic Surgery, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, 200025, P. R. China;

Corresponding author：

LI Hecheng, Email: lihecheng2000@hotmail.com

Keywords：

Malignant pleural mesothelioma; immunotherapy; clinical trails; review

DOI：

10.7507/1007-4848.202012052

Video：

Export PDF Favorites Scan Get Citation

Abstract Full text Figures/Tables Video References Cited by

In recent years, immune checkpoint inhibitor therapy has changed the treatment of various malignant tumors. Immunotherapy for specific targets currently plays an important role in melanoma, lung cancer and other tumors. Malignant pleural mesothelioma (MPM) is an aggressive malignant tumor. Although the treatments include surgery, chemotherapy and radiotherapy, the clinical efficacy is limited, and the prognosis of advanced patients is poor. With the application of monoclonal antibodies such as programmed death 1/programmed death ligand 1 and cytotoxic T-lymphocyte antigen 4, MPM patients have more treatment options. And compared with traditional chemotherapy, immunotherapy may have the effect of improving survival and shrinking tumors. This article will summarize the current clinical trials of immunotherapy in MPM, and explain the current application and progress of immunotherapy in MPM from both single-agent immunotherapy and combined immunotherapy.

Citation： CHEN Xiang, ZHANG Yajie, LI Hecheng. Application of immunotherapy in malignant pleural mesothelioma. Chinese Journal of Clinical Thoracic and Cardiovascular Surgery, 2022, 29(7): 935-938. doi: 10.7507/1007-4848.202012052 Copy

1.	Pastorino S, Yoshikawa Y, Pass HI, et al. A subset of mesotheliomas with improved survival occurring in carriers of BAP1 and other germline mutations. J Clin Oncol, 2018, 36(35): JCO2018790352.
2.	Xu R, Barg FK, Emmett EA, et al. Association between mesothelioma and non-occupational asbestos exposure: Systematic review and meta-analysis. Environ Health, 2018, 17(1): 90.
3.	Betti M, Casalone E, Ferrante D, et al. Germline mutations in DNA repair genes predispose asbestos-exposed patients to malignant pleural mesothelioma. Cancer Lett, 2017, 405: 38-45.
4.	Mazurek JM, Syamlal G, Wood JM, et al. Malignant mesothelioma mortality—United States, 1999-2015. MMWR Morb Mortal Wkly Rep, 2017, 66(8): 214-218.
5.	Smith JG. Predicting survival in malignant mesothelioma. Eur Respir J, 2012, 40(3): 799.
6.	陈香, 张亚杰, 李鹤成. NCCN 恶性胸膜间皮瘤临床实践指南 2020 年第 1 版更新解读. 中国胸心血管外科临床杂志, 2020, 27(4): 408-410.
7.	David S, Douglas E, Aggarwal C, et al. NCCN clinical practice guidelines in oncology: Malignant pleural mesothelioma version 1.2020 (2019-11-27). URL: https://www.nccn.org/professionals/physician_gls/pdf/mpm.pdf.
8.	Dong Y, Sun Q, Zhang X. PD-1 and its ligands are important immune checkpoints in cancer. Oncotarget, 2017, 8(2): 2171-2186.
9.	Cedrés S, Ponce-Aix S, Zugazagoitia J, et al. Analysis of expression of programmed cell death 1 ligand 1 (PD-L1) in malignant pleural mesothelioma (MPM). PLoS One, 2015, 10(3): e0121071.
10.	Mansfield AS, Roden AC, Peikert T, et al. B7-H1 expression in malignant pleural mesothelioma is associated with sarcomatoid histology and poor prognosis. J Thorac Oncol, 2014, 9(7): 1036-1040.
11.	Nguyen BH, Montgomery R, Fadia M, et al. PD-L1 expression associated with worse survival outcome in malignant pleural mesothelioma. Asia Pac J Clin Oncol, 2018, 14(1): 69-73.
12.	Rrapaj E, Giacometti L, Spina P, et al. Programmed cell death 1 ligand 1 (PD-L1) expression is associated with poor prognosis of malignant pleural mesothelioma patients with good performance status. Pathology, 2021, 53(4): 462-469.
13.	Zalcman G, Mazieres J, Margery J, et al. Bevacizumab for newly diagnosed pleural mesothelioma in the Mesothelioma Avastin Cisplatin Pemetrexed Study (MAPS): A randomised, controlled, open-label, phase 3 trial. Lancet, 2016, 387(10026): 1405-1414.
14.	Alley EW, Lopez J, Santoro A, et al. Clinical safety and activity of pembrolizumab in patients with malignant pleural mesothelioma (KEYNOTE-028): Preliminary results from a non-randomised, open-label, phase 1b trial. Lancet Oncol, 2017, 18(5): 623-630.
15.	Quispel-Janssen J, van der Noort V, de Vries JF, et al. Programmed death 1 blockade with nivolumab in patients with recurrent malignant pleural mesothelioma. J Thorac Oncol, 2018, 13(10): 1569-1576.
16.	Okada M, Kijima T, Aoe K, et al. Clinical efficacy and safety of nivolumab: Results of a multicenter, open-label, single-am, Japanese phaseⅡ study in malignant pleural mesothelioma (MERIT). Clin Cancer Res, 2019, 25(18): 5485-5492.
17.	Hassan R, Thomas A, Nemunaitis JJ, et al. Efficacy and safety of avelumab treatment in patients with advanced unresectable mesothelioma: Phase 1b results from the JAVELIN solid tumor trial. JAMA Oncol, 2019, 5(3): 351-357.
18.	Nowak AK, Lesterhuis WJ, Kok PS, et al. Durvalumab with first-line chemotherapy in previously untreated malignant pleural mesothelioma (DREAM): A multicentre, single-arm, phase 2 trial with a safety run-in. Lancet Oncol, 2020, 21(9): 1213-1223.
19.	Cantini L, Belderbos RA, Gooijer CJ, et al. Nivolumab in pre-treated malignant pleural mesothelioma: Real-world data from the Dutch expanded access program. Transl Lung Cancer Res, 2020, 9(4): 1169-1179.
20.	Pardoll DM. The blockade of immune checkpoints in cancer immunotherapy. Nat Rev Cancer, 2012, 12(4): 252-264.
21.	Calabrò L, Morra A, Fonsatti E, et al. Tremelimumab for patients with chemotherapy-resistant advanced malignant mesothelioma: An open-label, single-arm, phase 2 trial. Lancet Oncol, 2013, 14(11): 1104-1111.
22.	Calabrò L, Morra A, Fonsatti E, et al. Efficacy and safety of an intensified schedule of tremelimumab for chemotherapy-resistant malignant mesothelioma: An open-label, single-arm, phase 2 study. Lancet Respir Med, 2015, 3(4): 301-309.
23.	Maio M, Scherpereel A, Calabrò L, et al. Tremelimumab as second-line or third-line treatment in relapsed malignant mesothelioma (DETERMINE): A multicentre, international, randomised, double-blind, placebo-controlled phase 2b trial. Lancet Oncol, 2017, 18(9): 1261-1273.
24.	Das R, Verma R, Sznol M, et al. Combination therapy with anti-CTLA-4 and anti-PD-1 leads to distinct immunologic changes in vivo. J Immunol, 2015, 194(3): 950-959.
25.	Selby MJ, Engelhardt JJ, Johnston RJ, et al. Preclinical development of ipilimumab and nivolumab combination immunotherapy: Mouse tumor models, in vitro functional studies, and cynomolgus macaque toxicology. PLoS One, 2016, 11(9): e0161779.
26.	Scherpereel A, Mazieres J, Greillier L, et al. Nivolumab or nivolumab plus ipilimumab in patients with relapsed malignant pleural mesothelioma (IFCT-1501 MAPS2): A multicentre, open-label, randomised, non-comparative, phase 2 trial. Lancet Oncol, 2019, 20(2): 239-253.
27.	Disselhorst MJ, Quispel-Janssen J, Lalezari F, et al. Ipilimumab and nivolumab in the treatment of recurrent malignant pleural mesothelioma (INITIATE): Results of a prospective, single-arm, phase 2 trial. Lancet Respir Med, 2019, 7(3): 260-270.
28.	Calabrò L, Morra A, Giannarelli D, et al. Tremelimumab combined with durvalumab in patients with mesothelioma (NIBIT-MESO-1): An open-label, non-randomised, phase 2 study. Lancet Respir Med, 2018, 6(6): 451-460.
29.	Mankor JM, Disselhorst MJ, Poncin M, et al. Efficacy of nivolumab and ipilimumab in patients with malignant pleural mesothelioma is related to a subtype of effector memory cytotoxic T cells: Translational evidence from two clinical trials. EBioMedicine, 2020, 62: 103040.
30.	Baas P, Scherpereel A, Nowak AK, et al. First-line nivolumab plus ipilimumab in unresectable malignant pleural mesothelioma (CheckMate 743): A multicentre, randomised, open-label, phase 3 trial. Lancet, 2021, 397(10272): 375-386.

1. Pastorino S, Yoshikawa Y, Pass HI, et al. A subset of mesotheliomas with improved survival occurring in carriers of BAP1 and other germline mutations. J Clin Oncol, 2018, 36(35): JCO2018790352.
2. Xu R, Barg FK, Emmett EA, et al. Association between mesothelioma and non-occupational asbestos exposure: Systematic review and meta-analysis. Environ Health, 2018, 17(1): 90.
3. Betti M, Casalone E, Ferrante D, et al. Germline mutations in DNA repair genes predispose asbestos-exposed patients to malignant pleural mesothelioma. Cancer Lett, 2017, 405: 38-45.
4. Mazurek JM, Syamlal G, Wood JM, et al. Malignant mesothelioma mortality—United States, 1999-2015. MMWR Morb Mortal Wkly Rep, 2017, 66(8): 214-218.
5. Smith JG. Predicting survival in malignant mesothelioma. Eur Respir J, 2012, 40(3): 799.
6. 陈香, 张亚杰, 李鹤成. NCCN 恶性胸膜间皮瘤临床实践指南 2020 年第 1 版更新解读. 中国胸心血管外科临床杂志, 2020, 27(4): 408-410.
7. David S, Douglas E, Aggarwal C, et al. NCCN clinical practice guidelines in oncology: Malignant pleural mesothelioma version 1.2020 (2019-11-27). URL: https://www.nccn.org/professionals/physician_gls/pdf/mpm.pdf.
8. Dong Y, Sun Q, Zhang X. PD-1 and its ligands are important immune checkpoints in cancer. Oncotarget, 2017, 8(2): 2171-2186.
9. Cedrés S, Ponce-Aix S, Zugazagoitia J, et al. Analysis of expression of programmed cell death 1 ligand 1 (PD-L1) in malignant pleural mesothelioma (MPM). PLoS One, 2015, 10(3): e0121071.
10. Mansfield AS, Roden AC, Peikert T, et al. B7-H1 expression in malignant pleural mesothelioma is associated with sarcomatoid histology and poor prognosis. J Thorac Oncol, 2014, 9(7): 1036-1040.
11. Nguyen BH, Montgomery R, Fadia M, et al. PD-L1 expression associated with worse survival outcome in malignant pleural mesothelioma. Asia Pac J Clin Oncol, 2018, 14(1): 69-73.
12. Rrapaj E, Giacometti L, Spina P, et al. Programmed cell death 1 ligand 1 (PD-L1) expression is associated with poor prognosis of malignant pleural mesothelioma patients with good performance status. Pathology, 2021, 53(4): 462-469.
13. Zalcman G, Mazieres J, Margery J, et al. Bevacizumab for newly diagnosed pleural mesothelioma in the Mesothelioma Avastin Cisplatin Pemetrexed Study (MAPS): A randomised, controlled, open-label, phase 3 trial. Lancet, 2016, 387(10026): 1405-1414.
14. Alley EW, Lopez J, Santoro A, et al. Clinical safety and activity of pembrolizumab in patients with malignant pleural mesothelioma (KEYNOTE-028): Preliminary results from a non-randomised, open-label, phase 1b trial. Lancet Oncol, 2017, 18(5): 623-630.
15. Quispel-Janssen J, van der Noort V, de Vries JF, et al. Programmed death 1 blockade with nivolumab in patients with recurrent malignant pleural mesothelioma. J Thorac Oncol, 2018, 13(10): 1569-1576.
16. Okada M, Kijima T, Aoe K, et al. Clinical efficacy and safety of nivolumab: Results of a multicenter, open-label, single-am, Japanese phaseⅡ study in malignant pleural mesothelioma (MERIT). Clin Cancer Res, 2019, 25(18): 5485-5492.
17. Hassan R, Thomas A, Nemunaitis JJ, et al. Efficacy and safety of avelumab treatment in patients with advanced unresectable mesothelioma: Phase 1b results from the JAVELIN solid tumor trial. JAMA Oncol, 2019, 5(3): 351-357.
18. Nowak AK, Lesterhuis WJ, Kok PS, et al. Durvalumab with first-line chemotherapy in previously untreated malignant pleural mesothelioma (DREAM): A multicentre, single-arm, phase 2 trial with a safety run-in. Lancet Oncol, 2020, 21(9): 1213-1223.
19. Cantini L, Belderbos RA, Gooijer CJ, et al. Nivolumab in pre-treated malignant pleural mesothelioma: Real-world data from the Dutch expanded access program. Transl Lung Cancer Res, 2020, 9(4): 1169-1179.
20. Pardoll DM. The blockade of immune checkpoints in cancer immunotherapy. Nat Rev Cancer, 2012, 12(4): 252-264.
21. Calabrò L, Morra A, Fonsatti E, et al. Tremelimumab for patients with chemotherapy-resistant advanced malignant mesothelioma: An open-label, single-arm, phase 2 trial. Lancet Oncol, 2013, 14(11): 1104-1111.
22. Calabrò L, Morra A, Fonsatti E, et al. Efficacy and safety of an intensified schedule of tremelimumab for chemotherapy-resistant malignant mesothelioma: An open-label, single-arm, phase 2 study. Lancet Respir Med, 2015, 3(4): 301-309.
23. Maio M, Scherpereel A, Calabrò L, et al. Tremelimumab as second-line or third-line treatment in relapsed malignant mesothelioma (DETERMINE): A multicentre, international, randomised, double-blind, placebo-controlled phase 2b trial. Lancet Oncol, 2017, 18(9): 1261-1273.
24. Das R, Verma R, Sznol M, et al. Combination therapy with anti-CTLA-4 and anti-PD-1 leads to distinct immunologic changes in vivo. J Immunol, 2015, 194(3): 950-959.
25. Selby MJ, Engelhardt JJ, Johnston RJ, et al. Preclinical development of ipilimumab and nivolumab combination immunotherapy: Mouse tumor models, in vitro functional studies, and cynomolgus macaque toxicology. PLoS One, 2016, 11(9): e0161779.
26. Scherpereel A, Mazieres J, Greillier L, et al. Nivolumab or nivolumab plus ipilimumab in patients with relapsed malignant pleural mesothelioma (IFCT-1501 MAPS2): A multicentre, open-label, randomised, non-comparative, phase 2 trial. Lancet Oncol, 2019, 20(2): 239-253.
27. Disselhorst MJ, Quispel-Janssen J, Lalezari F, et al. Ipilimumab and nivolumab in the treatment of recurrent malignant pleural mesothelioma (INITIATE): Results of a prospective, single-arm, phase 2 trial. Lancet Respir Med, 2019, 7(3): 260-270.
28. Calabrò L, Morra A, Giannarelli D, et al. Tremelimumab combined with durvalumab in patients with mesothelioma (NIBIT-MESO-1): An open-label, non-randomised, phase 2 study. Lancet Respir Med, 2018, 6(6): 451-460.
29. Mankor JM, Disselhorst MJ, Poncin M, et al. Efficacy of nivolumab and ipilimumab in patients with malignant pleural mesothelioma is related to a subtype of effector memory cytotoxic T cells: Translational evidence from two clinical trials. EBioMedicine, 2020, 62: 103040.
30. Baas P, Scherpereel A, Nowak AK, et al. First-line nivolumab plus ipilimumab in unresectable malignant pleural mesothelioma (CheckMate 743): A multicentre, randomised, open-label, phase 3 trial. Lancet, 2021, 397(10272): 375-386.

Chinese Journal of Clinical Thoracic and Cardiovascular Surgery

Application of immunotherapy in malignant pleural mesothelioma

Abstract Full text Figures/Tables Video References Cited by

Previous Article

Next Article

Format

Content